Pacira Biosciences Inc Stock Price, News & Analysis

Pacira BioSciences (Nasdaq: PCRX) announced that on December 1, 2025 it granted inducement restricted stock unit awards to two newly hired employees under its Amended and Restated 2014 Inducement Plan, approved by the People & Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

The awards total an aggregate of 2,200 restricted stock units, each representing the contingent right to one share of common stock. The RSUs vest in four equal annual installments beginning December 1, 2026, and vesting is conditioned on continued employment and the terms of each award agreement.

Pacira BioSciences (NASDAQ: PCRX) reported 12-month results from a 30-patient randomized pilot comparing iovera° cryoneurolysis to radiofrequency ablation (RFA) for facet-mediated chronic low back pain. The study found significantly lower pain scores with iovera° at Day 180 (3.1 vs 5.4, p=0.01) and Day 360 (3.0 vs 6.1, p=0.01), and better functional outcomes by Oswestry Disability Index at Day 360 (10.1 vs 20.6, p=0.002). Fewer iovera° patients required additional spine injections after 180 days (45.5% vs 75%). No treatment-related adverse events were reported during 12 months. The trial was unblinded and device length limited use to lower BMI patients; a new FDA-cleared SmartTip for deeper lumbar access was noted.

Pacira BioSciences (Nasdaq: PCRX) will participate in analyst-led fireside chats at two upcoming healthcare conferences: the Jefferies London Healthcare Conference on Nov 18, 2025 at 1:30 PM GMT (8:30 AM ET) and the 37th Annual Piper Sandler Healthcare Conference on Dec 2, 2025 at 1:30 PM ET.

Live audio of both events will be available on the company’s Events page at investor.pacira.com, and webcasts will be replayable for two weeks after each event.

Pacira BioSciences (NASDAQ: PCRX) reported Q3 2025 revenues of $179.5M and updated full-year guidance on November 6, 2025. The company raised its full-year non-GAAP gross margin to 80–82% and reiterated other ranges while narrowing total revenue to $725M–$735M. Q3 results included EXPAREL net sales of $139.9M (volume +9%), adjusted EBITDA of $49.4M, GAAP net income of $5.4M (EPS $0.12), and non-GAAP net income of $31.8M (EPS $0.72 basic). Pacira repurchased 2.0M shares for $50.0M, ended the quarter with $246.3M cash, completed enrollment in Part A of its Phase 2 ASCEND PCRX-201 study, and in‑licensed AMT-143 under a deal with a $5.0M upfront payment.

Pacira BioSciences (Nasdaq: PCRX) announced it has concluded patient enrollment in Part A of the Phase 2 ASCEND study of PCRX-201 for osteoarthritis of the knee. Part A randomized ~45 patients 1:1:1 to two dose levels (1.4×10¹⁰ GC and 1.4×10¹¹ GC) or saline, with steroid pretreatment for all cohorts. The study will enroll ~135 patients across Parts A and B; Part B will randomize ~90 patients using commercial-scale manufactured drug product. The primary endpoint is safety through Week 52; secondary endpoints include pain and function at Weeks 38 and 52 (NRS, WOMAC, KOOS). Pacira expects topline Part A results before the end of 2026 and will follow participants for five years.

Pacira BioSciences (NASDAQ: PCRX) entered an exclusive worldwide license and collaboration agreement with AmacaThera to develop and commercialize AMT-143, a long-acting formulation of ropivacaine for postsurgical pain control.

The company said AMT-143 complements EXPAREL, advances Pacira's 5x30 pipeline strategy, and has a Phase 2 program expected to begin in 2026. Management indicated the asset could be meaningfully accretive to cash flow and earnings within the 5x30 timeframe.

Pacira (Nasdaq: PCRX) will report third quarter 2025 financial results after U.S. market close on Thursday, November 6, 2025. The company will host a live conference call and webcast at 4:30 p.m. ET following the release.

Investors who wish to ask questions by phone must pre-register to receive dial-in details and a PIN. A live audio webcast will be available on the company’s Events page at investor.pacira.com. A replay of the webcast will be accessible on the Pacira website for about two weeks after the call.